HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B
Lilly Yuen, Peter A Revill, Gillian Rosenberg, Josef Wagner, Margaret Littlejohn, Julianne Bayliss, Kathy Jackson, Susanna K Tan, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Ed Gane, Henry LY Chan, Xin Li, Scott Bowden, Stephen Locarnini, Alexander Thompson
JOURNAL OF VIRAL HEPATITIS | WILEY | Published : 2020
Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have been associated with adverse outcomes, including HCC; however, the frequency of these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next-generation sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects were performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects (genotype B/C 55%/45%, median HBV-DNA 8.5 log10 IU/mL, median HBsAg 4.8 log10 IU/mL, m..View full abstract
The study was funded in part by Gilead Sciences.